| Literature DB >> 35681322 |
Weiyang Kuang1, Jiajia Yang1, Zhiyuan Liu1, Jinzi Zeng1, Xuewei Xia1, Xiaodan Chen1, Saiyi Zhong2, Riming Huang1.
Abstract
Catechin possesses a potential anti-inflammatory activity, but its anti-inflammatory mechanism is still unclear. Herein, the analysis of network pharmacology showed that catechin might mediate ferroptosis on macrophages to exhibit a significant anti-inflammatory effect on RAW264.7. The metabolomics further indicated that catechin might influence ferroptosis by activating two pathways of cysteine and methionine metabolism and glutathione metabolism, and inhibiting the pathway of ferroptosis to promote the reduction of l-methionine-s-oxide and s-glutathionyl-l-cysteine, and the reduction and synthesis of γ-glutamylcysteine. Furthermore, related proteins (MSRA, CDR, GSR and GCL) in three metabolic pathways and ferroptosis-related proteins (GPX4 and SLC7A11) might be relevant to catechin through molecular docking. Thus, we speculate that catechin plays an anti-inflammatory effect through mediating ferroptosis on RAW264.7, which still needs further focus on the detailed molecular mechanism.Entities:
Keywords: anti-inflammatory; catechin; ferroptosis; molecular mechanism
Year: 2022 PMID: 35681322 PMCID: PMC9180002 DOI: 10.3390/foods11111572
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Anti-inflammatory effect of catechin on RAW264.7 cells. (A) Cell viability. NS means no significance. (B) NO production. **** p < 0.0001, other groups vs. control group, aspirin (40 μg/mL) adding group vs. LPS (2.5 μg/mL), and catechin (20 μg/mL and 40 μg/mL) adding groups vs. LPS (2.5 μg/mL); ** p < 0.01, catechin (10 μg/mL) adding group vs. LPS (2.5 μg/mL).
Figure 2Network pharmacology analysis of catechin on inflammation. (A) Potential targets and PPI network. (B) 15 core targets. (C) Bubble diagram of GO enrichments. (D) Sankey diagram of KEGG pathways. (E) KEGG pathways related to ferroptosis.
Information of the core targets.
| Gene Name | UniProt ID | Protein Name | Degree Centrality (DC) |
|---|---|---|---|
| Akt1 | P31750 | RAC-alpha serine/threonine-protein kinase | 11 |
| Hsp90aa1 | P07901 | Heat shock protein HSP 90-alpha | 10 |
| Esr1 | P19785 | Estrogen receptor | 10 |
| Hsp90ab1 | P11499 | Heat shock protein HSP 90-beta | 9 |
| Esr2 | O08537 | Estrogen receptor beta | 6 |
| Nos3 | P70313 | Nitric oxide synthase, endothelial | 5 |
| Itgb1 | P09055 | Integrin beta-1 | 5 |
| Cdk1 | P11440 | Cyclin-dependent kinase 1 | 5 |
| Ncoa1 | P70365 | Nuclear receptor coactivator 1 | 5 |
| Ahr | P30561 | Aryl hydrocarbon receptor | 4 |
| Chuk | Q60680 | Inhibitor of nuclear factor kappa-B kinase subunit alpha | 4 |
| Cdk2 | P97377 | Cyclin-dependent kinase 2 | 4 |
| Chek1 | O35280 | Serine/threonine-protein kinase Chk1 | 4 |
| Hspa2 | P17156 | Heat shock-related 70 kDa protein 2 | 3 |
| Actb | P60710 | Actin, cytoplasmic 1 | 3 |
Figure 3Metabolism analysis of catechin treating on macrophage RAW264.7 cells. (A) Volcano plots of differential metabolites in BT vs. BP group and BP vs. BC group. (B) Hierarchical cluster figures of differential metabolites. (C) Bubble diagram of metabolic pathways. (D) Metabolic pathways were related to ferroptosis and the enrichments of differential metabolites.
The information of 16 significantly different metabolites.
| Differential Metabolites | VIP (VIP > 1) | Fold Change (FC) | BP vs. BC Trend | BT vs. BP Trend | |
|---|---|---|---|---|---|
| 17a-Estradiol | 1.23640275 | 0.02890117 | 0.63 | up 1 | down 2 |
| Xanthylic acid | 1.378648746 | 0.007098714 | 0.3 | up | down |
| Porphobilinogen | 1.228633844 | 0.041716502 | 0.66 | up | down |
| 1,2,3-Trihydroxybenzene | 1.408122971 | 0.004251857 | 0.33 | up | down |
| Ureidosuccinic acid | 1.479845722 | 5.71205 × 10−6 | 0.25 | up | down |
| Guanosine | 1.381268976 | 0.041686027 | 0.29 | up | down |
| GMP | 1.387077366 | 0.002758109 | 0.1 | up | down |
|
| 1.350657845 | 0.011718718 | 0.39 | up | down |
| Inosine | 1.429164585 | 0.00206919 | 0.31 | up | down |
|
| 1.411921836 | 0.003672009 | 0.37 | up | down |
| (S)-3-Methyl-2-oxopentanoic acid | 1.226482998 | 0.033345036 | 0.24 | up | down |
| 2-Hydroxybutyric acid | 1.251116465 | 0.037188342 | 0.58 | up | down |
| Mannitol | 1.449246459 | 0.001098845 | 0.2 | up | down |
| Deoxyuridine | 1.242857502 | 0.041777372 | 1.04 | down | up |
| D-Mannose | 1.332811288 | 0.008474664 | 3.32 | down | up |
|
| 1.350096846 | 0.007306674 | 2.77 | down | up |
1 Up means up-regulation of the differential metabolites. 2 Down means down-regulation of the differential metabolites.
Figure 4Molecular binding modes of catechin with proteins were presented by 3D and 2D structures. (A) Binding modes of MSRA-catechin complex. (B) Binding modes of CDR-catechin complex. (C) Binding modes of GSR-catechin complex. (D) Binding modes of GCL-catechin complex. (E) Binding modes of SLC7A11-catechin complex. (F) Binding modes of GPX4-catechin complex.
The binding energy for catechin with related proteins.
| Compound | Protein | Amino Acid Residues | Docking Score | Binding Energy (kcal/mol) |
|---|---|---|---|---|
| Catechin | MSRA | Lys79, Asn138, Asp149, Asp150 | −5.587 | −31.47 |
| Catechin | CDR | Asp35, Asn42, Arg112, Asp112, Ser112, Ala115 | −8.428 | −55.50 |
| Catechin | GSR | Ser52, Cys80, Val83, Cyt85, Lys88, Ser199 | −6.949 | −52.12 |
| Catechin | GCL | Arg185, Asn247, Arg296, Ser403, Trp406, Arg410, Arg427 | −5.950 | −42.67 |
| Catechin | SLC7A11 | Val57, Ser60, Gly61, Ile134, Arg135, Tyr244, Tye251, Ser393 | −6.229 | −44.74 |
| Catechin | GPX4 | Gly47, Lys48, Trp136 | −3.744 | −33.38 |
Figure 5Hypothetical molecular mechanism of ferroptosis mediated anti-inflammatory process of catechin (created with https://app.biorender.com/ (accessed on 18 April 2022)). Lines with red arrowheads represent activation and lines with bars at the end denote inhibition.